Leerink Partnrs Issues Optimistic Forecast for SLDB Earnings

Solid Biosciences Inc. (NASDAQ:SLDB) – Equities researchers at Leerink Partnrs raised their Q3 2025 earnings per share estimates for Solid Biosciences in a report released on Wednesday, August 13th. Leerink Partnrs analyst J. Schwartz now forecasts that the company will post earnings per share of ($0.43) for the quarter, up from their prior estimate of ($0.60). The consensus estimate for Solid Biosciences’ current full-year earnings is ($2.84) per share. Leerink Partnrs also issued estimates for Solid Biosciences’ Q4 2025 earnings at ($0.45) EPS, FY2025 earnings at ($1.85) EPS and FY2026 earnings at ($1.92) EPS.

Solid Biosciences (NASDAQ:SLDB) last announced its quarterly earnings results on Tuesday, August 12th. The company reported ($0.42) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.51) by $0.09.

Several other analysts also recently weighed in on SLDB. Chardan Capital reissued a “buy” rating and issued a $15.00 target price on shares of Solid Biosciences in a report on Thursday. Citigroup began coverage on Solid Biosciences in a report on Thursday, June 26th. They issued a “buy” rating and a $14.00 target price for the company. Wedbush reduced their target price on Solid Biosciences from $17.00 to $14.00 and set an “outperform” rating for the company in a report on Wednesday, August 13th. HC Wainwright restated a “buy” rating and issued a $20.00 price target on shares of Solid Biosciences in a research report on Tuesday, June 17th. Finally, Wall Street Zen upgraded Solid Biosciences from a “sell” rating to a “hold” rating in a research report on Saturday. One investment analyst has rated the stock with a hold rating, ten have assigned a buy rating and two have given a strong buy rating to the company. According to MarketBeat, Solid Biosciences presently has an average rating of “Buy” and a consensus price target of $15.00.

Solid Biosciences Stock Performance

Solid Biosciences stock opened at $6.11 on Monday. Solid Biosciences has a fifty-two week low of $2.41 and a fifty-two week high of $10.37. The company has a market capitalization of $475.79 million, a P/E ratio of -2.18 and a beta of 2.44. The stock has a 50-day simple moving average of $5.62 and a 200-day simple moving average of $4.45.

Hedge Funds Weigh In On Solid Biosciences

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. JPMorgan Chase & Co. increased its position in Solid Biosciences by 9,393.8% during the 4th quarter. JPMorgan Chase & Co. now owns 955,932 shares of the company’s stock worth $3,824,000 after purchasing an additional 945,863 shares during the period. Renaissance Technologies LLC increased its position in Solid Biosciences by 12.7% during the 4th quarter. Renaissance Technologies LLC now owns 82,493 shares of the company’s stock worth $330,000 after purchasing an additional 9,281 shares during the period. Bank of America Corp DE increased its position in Solid Biosciences by 87.9% during the 4th quarter. Bank of America Corp DE now owns 83,471 shares of the company’s stock worth $334,000 after purchasing an additional 39,056 shares during the period. Allianz Asset Management GmbH acquired a new position in Solid Biosciences during the 1st quarter worth approximately $100,000. Finally, Invesco Ltd. acquired a new position in Solid Biosciences during the 4th quarter worth approximately $49,000. Institutional investors and hedge funds own 81.46% of the company’s stock.

Solid Biosciences Company Profile

Solid Biosciences Inc, a life science company, develops therapies for neuromuscular and cardiac diseases in the United States. The company's lead product candidate is SGT-003, a gene transfer candidate for the treatment of Duchenne muscular dystrophy; and SGT-501 to treat Catecholaminergic polymorphic ventricular tachycardia.